CME

Host: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric appr...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Samantha Denäe A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care...

Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine...

Guest: Michael J. Mauro, MD Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the unde...

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for...

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Guru...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci This program is no longer available for credit. Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and impr...

Guest: Ana Barac, MD, PhD The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

Host: Frederic Rahbari-Oskoui, MD, MSc This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Fouad T. Chebib, MD Guest: Pranav S. Garimella, MD This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Mark Socinski, MD Guest: Patrick Forde, M.B.B.Ch. Guest: Karen Reckamp, MS, MD Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-...

Host: Meyeon Park, MD, MAS Host: Anjay Rastogi, MD, PhD This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing education credit.

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: James B. Bussel, MD This program is no longer available for credit. Program Chairman: Roberto Romero, MD, DMedSci Chief, Perinatology Research Branch Division of Maternal-Fetal Medicine and Obstetrics Division of Intramural Research NICHD/NIH/DHHS Editor-in-Chief for Obstetrics The American Journal of Obstetrics and Gynecology As the platelet equivalen...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Kenneth J. Moise Jr., MD This program is no longer available for credit. Program Chairman: Roberto Romero, MD, DMedSci Chief, Perinatology Research Branch Division of Maternal-Fetal Medicine and Obstetrics Division of Intramural Research NICHD/NIH/DHHS Editor-in-Chief for Obstetrics The American Journal of Obstetrics and Gynecology How well do you unde...